Allergan defuses Botox threat with $195M Bonti buy by Amirah Al Idrus Friday, September 14, 2018 Allergan will fork over $195 million for Bonti, a startup founded by former Allergan executives focused on creating a new botulinum neurotoxin.
Helmed by former Allergan execs, Bonti bags $15M by Amirah Al Idrus Wednesday, January 24, 2018 Ex-Allergan executives raised $15.5 million for Bonti, a startup working on a unique botulinum neurotoxin.
Evolus plans $75M IPO to bring Botox biosimilar to market by Nick Paul Taylor Wednesday, January 10, 2018 The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market.
Revance’s rival to Allergan’s Botox aces phase 3 by Nick Paul Taylor Tuesday, December 5, 2017 The effect of the neuromodulator on wrinkles lasted for six months, suggesting it poses a threat to Allergan’s blockbuster Botox franchise.
Dodgy stem cell clinics; New CMO for Context—News of Note by Ben Adams Wednesday, July 19, 2017 Check out the rest of Wednesday's news of note.
Video Interview—Allergan’s R&D officer David Nicholson by Ben Adams Monday, July 10, 2017 We delve into the R&D strategy for Allergan, a company that nearly became part of Pfizer last year.
Dermira posts broadly positive results for excessive sweat drug by Ben Adams Thursday, June 2, 2016 The Californian biotech Dermira says its experimental sweat drug DRM04 passed one Phase III test but narrowly missed its target on a second--although analysts believe this will still be good enough to reap an FDA approval.
